<DOC>
	<DOC>NCT02485873</DOC>
	<brief_summary>To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting</brief_summary>
	<brief_title>Real-Life Evidence on Stroke Prevention in SPAF</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Age â‰¥18 years on the day of the first prescription of the study drug (= index date) during study selection window Diagnosis of NVAF on start date of study or anytime during 365 days before this date Availability of followup at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date) Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window. Patients with valvular AF Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date Prescription of more than one OAC on the index date or switch to another OAC during the followup period Prescriptions of &lt; 15mg rivaroxaban at index date or during the followup period for patients in rivaroxaban cohort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Non-valvular atrial fibrillation (NVAF)</keyword>
	<keyword>Pevention</keyword>
	<keyword>Stroke</keyword>
</DOC>